8 results about "Gained weight" patented technology

The disclosure relates to compositions comprising a phentermine and a unicyclic aminoketone and methods of use thereof. The methods of use include inducing weight loss or reducing weight gain in a human subject. The unicyclic aminoketone may be diethylpropion or bupropion. In some embodiments, the compositions further include tadalafil or naltrexone.

The invention discloses highly acetylated glucomannan and application thereof in preparation of a product with an effect of relieving prediabetes mellitus, and belongs to the technical field of medicines. In-vivo experiments prove that the glucomannan with high acetylation degree has the effect of relieving the prediabetic stage, which is specifically reflected in weight gain of mice in the prediabetic stage, regulation of blood glucose metabolism, improvement of glucose tolerance and insulin resistance, regulation of blood lipid metabolism, protection of liver and pancreatic tissues and reduction of epididymal fat cell size. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

The present application discloses a two-arm branched fatty acid side chain, a receptor agonist modified therewith, and a use thereof. By adjusting the number and structure of side chain arms of the fatty acid chain, optimizing the type of a core molecule, and using the fatty acid chain to modify a receptor agonist, the present application significantly improves the physical and chemical stability of the receptor agonist and the therapeutic effect of the receptor agonist on reducing blood glucose and body weight. The fatty acid chain and the receptor agonist modified therewith disclosed in the present application can reduce blood glucose levels and improve sugar tolerance and has the effects of controlling appetite, food intake, and caloric intake, increasing energy consumption, preventing weight gain, promoting weight loss, and reducing excess body weight. In addition, the fatty acid chain and the receptor agonist modified therewith disclosed in the present application have relatively long half-life and can effectively prolong in vivo drug actions.

The invention discloses application of long-chain non-coding LncRNA LMRF in improvement of chicken weight and slaughter performance, and belongs to the technical field of gene engineering. Through specific overexpression of LncRNA LMRF in chicken liver tissues, compared with a control group, the average weight of chicken in an experimental group during slaughtering is increased by 185.00 g, the total eviscerating weight is increased by 179.38 g, the pectoral muscle rate is increased by 1.31 times, and the leg muscle rate is increased by 1.20 times. The long-chain non-coding LncRNA LMRF promotes growth and development of chicken muscles by increasing the muscle fiber diameter and muscle fiber area, so that the weight and slaughter performance of the chicken are improved.

An embodiment relates to a composition for promoting height growth comprising an Artemisia dubia Wall. extract as an active ingredient, and may provide a composition for promoting height growth comprising an Artemisia dubia Wall. extract as an active ingredient, which has excellent effects of increasing body weight, increasing the tibial growth plate, increasing the femoral growth plate, and increasing the expression of a blood growth factor.

The present invention relates to antisense oligonucleotides (AONs) that can mediate RNA editing by binding to a target RNA nucleic acid molecule in a cell and recruiting an endogenous deaminating enzyme in the cell to deaminate a target adenosine in the target RNA molecule to an inosine. The target RNA molecule is a transcript molecule from the pro-opiomelanocortin (POMC) gene encoding the β-MSH peptide. Preferably, the RNA editing changes a tyrosine to a cysteine at position 221 (Y221C) in the POMC prohormone, which results in a loss-of-function of the encoded β-MSH peptide. In turn, treatment using the AONs as disclosed will result in gain of body weight and increased BMI, thereby lowering the risk of suffering from weight loss related metabolic disorders such as cachexia.

This invention relates to a morel lectin, its preparation method, and its application, belonging to the field of biotechnology. The amino acid sequence of the morel lectin of this invention is shown in SEQ ID NO.1. The morel lectin is obtained by ultrafiltration, saturated ammonium sulfate precipitation, dialysis, microporous membrane filtration, Q Beads 6FF ion chromatography, dialysis, and freeze-drying of the supernatant after homogenizing morel mushrooms with water. The morel lectin is used to treat non-alcoholic fatty liver disease (NAFLD), inhibiting weight gain, reducing hepatomegaly, lowering blood lipid levels, improving obesity symptoms, reducing hepatic steatosis and liver function damage, and effectively treating NAFLD.

The present invention relates to a composition for promoting body height growth, which comprises an Artemisia dubia extract as an active ingredient, and provides a composition for promoting body height growth, the present invention relates to a composition containing, as an active ingredient, an Artemisia dubia extract having excellent effects of increasing body weight, increasing tibia epiphyseal plate, increasing femoral epiphyseal plate, and increasing expression of growth factors in blood.